Health June

• The FDA has granted a new indication for the drug Tzield, expanding its use to patients who have already progressed to Stage 3 type 1 diabetes. • This latest approval aims to preserve residual beta cell function, building on previous expansions in April 2026 that extended the drug's use to children as young as one year old. • The decision was based on the PROTECT trial, which demonstrated a statistically significant effect on C-peptide, a surrogate endpoint used to predict clinical benefit.

• A new study reveals that Texas's abortion ban has led to a 2.52 percentage-point increase in maternal mental health issues, with the impact more than doubling for mothers using Medicaid or CHIP. • Data presented by Dr. Julie Kanter at the European Hematology Association 2026 Congress shows that current clinical trial eligibility for sickle cell disease (SCD) therapies excludes 90% of adults living with the condition. • These findings highlight critical systemic gaps in healthcare equity, specifically regarding maternal psychiatric support and access to cutting-edge genetic therapies for SCD.

• The FDA approved a third over-the-counter version of naloxone nasal spray on Tuesday, June 16, to increase accessibility and reduce costs for overdose reversal. • Separately, a reported disruption in breast biopsy services is expected to impact patient care and may necessitate adjustments to clinical management. • These developments highlight critical shifts in public health accessibility and the operational challenges facing diagnostic medical services.

• A recent health equity roundup highlights critical gaps in US healthcare, noting that nonmetropolitan areas have 44.4% fewer patient-facing workers per 10,000 residents than urban centers. • Data from the 2019-2023 American Community Survey reveals a stark imbalance: rural areas house 13.8% of the population but only 8.4% of the healthcare workforce. • Experts emphasize that meeting the WHO goal of reducing hepatitis B mortality by 65% requires increased investment in vaccinations, screenings, and stigma reduction.

• The June 12, 2026, public health update reports on a current outbreak of the Bundibugyo virus disease and the introduction of new clinical guidelines for CKM syndrome. • The report covers critical developments across infectious disease surveillance, prevention strategies, chronic disease management, and emerging medical technologies. • These updates are vital for healthcare providers and policymakers to implement the latest clinical standards and contain the viral spread.

• Gavi CEO Sania Nishtar and CEPI CEO Richard Hatchett have announced an urgent three-part response to an Ebola outbreak in the Democratic Republic of the Congo (DRC). • The outbreak is caused by the rare Bundibugyo virus, for which there are currently no approved vaccines or medical therapies. • This situation is critical because the lack of specific treatments necessitates an immediate assessment of whether existing Ebola vaccines provide cross-protection.

• Public Health Today's June 5, 2026 update reports on a current Ebola outbreak in the Democratic Republic of the Congo and the release of Phase 3 clinical data for the pancreatic cancer drug daraxonrasib. • Researchers at McMaster University have isolated a new compound from *Streptomyces rimosus* designed to combat antibiotic-resistant bacteria. • A new vector-control approach is being developed to suppress disease-carrying mosquito populations without using conventional insecticides, addressing the growing threat of insecticide resistance.

• Federal initiatives have expanded a drug-price transparency tool and proposed a $50 per month access plan for eligible Medicare beneficiaries using GLP-1 medications. • The new pricing proposal is scheduled to take effect in July 2026, though debates continue regarding actual savings and remaining affordability gaps. • The weekly roundup also highlights critical health equity issues, including cancer trauma, abortion cost disparities, and the economic impact of food insecurity.

• An Ebola outbreak in the Democratic Republic of Congo has sickened over 1,000 people and resulted in nearly 250 deaths. • A new study clarifies that while parental depression is strongly linked to child neurodevelopmental disorders such as autism, the use of antidepressant medications is not a cause. • These findings directly challenge claims made by RFK Jr. regarding the impact of antidepressants on child development.

• The European HealthTech sector experienced a surge of momentum during the week of June 5, 2026, marked by a massive growth round aimed at reducing administrative fragmentation and clinical workflow inefficiencies. • Key industry activity was driven by the aftermath of the MedTech Forum 2026 in Stockholm and a significant legislative clash regarding the regulation of artificial intelligence. • New structural updates were introduced to increase the attractiveness of the European market for medical hardware providers.

• In the phase III INDIGO trial, the investigational monoclonal antibody obexelimab substantially outperformed a placebo in treating immunoglobulin (Ig)G4-related disease. • This development positions obexelimab to compete with the only drug currently approved for the condition, potentially offering patients a new therapeutic option. • Separately, the CDC and state partners published a report in Morbidity and Mortality Weekly Report urging clinicians to increase screening for brucellosis.